Gotur

Quick links to important sections

Gotur

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gotur

Property Description
Active ingredient Cyclizine (e.g., Hydrochloride or Lactate)
Form Oral (tablets, liquid) and Parenteral (injection)
Pharmacological class First-generation Antihistamine (H₁-antagonist), Antiemetic
General purpose Relief from nausea, vomiting, and dizziness/vertigo
Origin Synthetic organic compound

The Core Identity and Classification of Gotur

Gotur is a medication whose active ingredient, Cyclizine, is fundamentally classified as a first-generation antihistamine and a potent antiemetic drug. This dual classification establishes its primary function as a central nervous system-acting agent used to control the body's sickness responses and mitigate symptoms related to imbalance. The efficacy of Cyclizine in rapidly addressing these symptoms is clinically recognized and supported by pharmacological studies.

Cyclizine is a synthetic organic compound derived from the piperazine chemical class. The medication's anti-nausea and antiemetic actions are considered reliable, supporting its role in palliative care. This utility reflects the recognition of Cyclizine as a necessary and important drug for general health care needs.

Composition and Available Drug Forms

The active substance in Gotur is Cyclizine, which is a single active ingredient product typically formulated as a salt. It is prepared as Cyclizine Hydrochloride for oral use (such as tablets) and as Cyclizine Lactate for sterile injection solutions, simplifying use and management.

This medication is manufactured in various high-level pharmaceutical preparations, including oral solid forms (such as tablets) and parenteral formulations (injection solutions). This diversity permits administration via both the oral route for common use and the intramuscular or intravenous routes in professional clinical settings.

General Purpose: Addressing Nausea and Dizziness

The general purpose of Gotur is to provide effective relief from the core symptoms of nausea, vomiting, and dizziness. It functions as a foundational antiemetic and antivertigo compound, designed to stabilize the user's equilibrium and abate feelings of queasiness.

This benefit is achieved by Cyclizine's ability to exert an influence on the two major control areas: the labyrinth apparatus (inner ear balance network) and the brain's Chemoreceptor Trigger Zone (CTZ). By dampening the signals originating from both the inner ear and the central trigger zone, the medicine directly inhibits the command centers responsible for initiating sickness and spinning sensations.

Regulatory References

  1. WHO Essential Medicines

What side effects are possible with Gotur?

Possible side effects and safety information

The safety profile of Gotur is formally documented in official prescribing information based on its classification as a first-generation antihistamine with anticholinergic properties. Adverse reactions are classified according to physiological systems and occurrence frequency.

Classification of Adverse Reactions

Side effects affecting the Nervous System and Psychiatric domains are commonly documented. These include drowsiness (somnolence), headache, incoordination, and dizziness. Additional reported psychiatric effects include disorientation, restlessness, nervousness, insomnia, and euphoria. Hallucinations have been documented, particularly when regulatory dosage recommendations are exceeded.

Anticholinergic effects are frequently reported in the Gastrointestinal system, specifically dryness of the mouth and constipation. Urinary retention is also noted under Renal and Urinary disorders.

Many specific effects, including less frequent ones, are reported with a frequency of Not Known in regulatory summaries, meaning incidence cannot be estimated accurately from available data.

Serious Safety Considerations

Official labeling highlights the potential for more serious adverse effects. These include severe hypersensitivity reactions such as anaphylaxis and angioedema. Effects on the Cardiovascular system include tachycardia, palpitations, and arrhythmias. Reports of hepatic dysfunction (jaundice, hepatitis), convulsions, and apnoea are also formally documented as adverse events.

Population and Contextual Safety Notes

Safety notes include specific considerations for certain groups. Older adults are generally considered more sensitive to adverse effects such as sedation, dizziness, dry mouth, and urinary retention. In the pediatric population, a paradoxical effect of hyperexcitability has been noted, and younger children are more susceptible to convulsions in instances of acute toxicity. The label also notes that the antiemetic property of the active ingredient may increase the toxicity of alcohol.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Gotur (Cyclizine) is officially documented to result from acute toxicity affecting both the Central Nervous System (CNS) and the body's peripheral anticholinergic system.

Documented Manifestations and Severe Outcomes

The clinical presentation of an overdose is characterized by a cluster of CNS effects, including severe disorientation, hyperexcitability, impaired judgment, and auditory or visual hallucinations. Peripheral signs such as dry mouth, tachycardia (fast heart rate), blurred vision, and urinary retention are also documented. In severe cases, the clinical course may escalate to life-threatening events, including convulsions, arrhythmias (irregular heartbeat), respiratory depression, and decreased consciousness.

Emergency Action Required

Regulatory authorities mandate that in the event of a suspected overdose, immediate medical attention must be sought. This action requires contacting a healthcare professional or the nearest hospital emergency department immediately.

Official Management and Population Risk

Overdose management is specified as symptomatic and supportive, which may include procedures such as gastric lavage or the use of parenteral anticonvulsant therapy to control seizures, as no specific antidote is known. The official labeling highlights that younger children are more susceptible to convulsions compared to adults, particularly when the ingested dose exceeds the high threshold of 40 mg/kg of body weight.

Therapeutic Uses of Gotur

What Gotur Treats: Main Uses and Benefits

Easing Sudden Symptomatic Discomfort

Gotur is generally used in situations involving certain distressing symptoms that arise suddenly or intensify rapidly. It helps address symptom clusters that may appear and create noticeable interference with daily comfort, providing supportive relief when symptoms become more noticeable. Clinical scenarios often involve acute episodes of symptoms related to systemic imbalance, symptoms associated with acute or episodic changes, and symptoms that become more disruptive during flare-ups.

Support for Episodic Tension and Distress

This medicine is applied across domains where additional symptomatic support is needed during periods of increased physiological or emotional tension. It is commonly used for managing conditions involving episodic or fluctuating manifestations in situations where patients experience symptomatic discomfort.

“Gotur assists with maintaining functional stability when symptoms are more noticeable.”

Improving Day-to-Day Comfort

By addressing disruptive symptom manifestations, Gotur provides support that helps ease the overall symptom burden. It contributes to easing the overall symptom load during periods of heightened or momentarily overwhelming symptoms.

Quick Fact: Supports Symptomatic Relief

Regulatory References

  1. NIH StatPearls overview on antiemetics

Eligibility and Restrictions for Use

Who Can and Cannot Use Gotur?

This section summarizes the official population eligibility and non-eligibility rules for Gotur (Cyclizine), as documented in governmental regulatory sources.


Eligibility Scope

Category Eligibility Rule (Strictly Regulatory Wording)
Populations for Whom Use is Allowed Adults and children aged 6 years and over are the approved populations for standard use. Older adults typically use the normal adult regimen.
Populations for Whom Use is Contraindicated Patients with known hypersensitivity to Cyclizine or any excipients must not use the medicine. It is also contraindicated in the presence of acute alcohol intoxication and should be avoided in patients with Porphyria.
Condition-Specific Eligibility Rules Use requires caution and appropriate monitoring in patients with glaucoma, urinary retention (including due to prostatic enlargement), obstructive disease of the gastrointestinal tract, hepatic disease, epilepsy, and certain severe heart conditions.
Age-Related Eligibility Rules Children less than 6 years of age are generally not recommended for the oral tablet formulation.
Pregnancy and Lactation Eligibility Status Pregnancy: The manufacturer advises avoidance; FDA labeling has cited a Pregnancy Category B. Lactation: Cyclizine is excreted in human milk; the amount has not been quantified.

Connection to the Overall Eligibility Profile

Regulatory documents define two primary user groups: approved users (aged 6 years and over) and prohibited users (those with formal contraindications). For all other approved users, the label imposes conditional use rules, explicitly requiring caution and monitoring in patients with specific pre-existing conditions sensitive to the drug’s anticholinergic activity, such as glaucoma or urinary retention.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Additive Central Nervous System (CNS) Effects The interaction profile for Gotur is defined by pharmacodynamic effects, primarily the potential for additive CNS depression. Co-administration with other CNS depressants, such as hypnotics, tranquilizers, anaesthetics, antipsychotics, and barbiturates, may result in pronounced effects. Specifically, regulatory documentation notes that Cyclizine enhances the soporific effect of Pethidine and may counteract the haemodynamic benefits of other Opioid Analgesics.

Anticholinergic Action Due to its inherent anticholinergic activity, co-administration with other anticholinergic/antimuscarinic drugs may cause an additive antimuscarinic action. This is noted in official labeling for substances such as Atropine and certain classes of antidepressants (including tricyclics and MAOIs), which can enhance anticholinergic effects.

Toxicity Masking and Formal Restriction The anti-emetic property of Cyclizine introduces the risk of masking the warning signs of damage caused by ototoxic drugs, including aminoglycoside antibacterials. This symptom-masking effect also contributes to the formal regulatory contraindication with acute alcohol intoxication, as the anti-emetic action may increase the toxicity of alcohol by concealing symptoms.

Mechanism of Action

Selective Inhibition of Renal Urate Transport

Gotur's primary mechanism involves the selective inhibition of Urate Transporter 1 (URAT1), a protein situated on the luminal surface of kidney proximal tubule cells. By acting as a selective inhibitor, the drug blocks the function of URAT1, which mediates the reabsorption of filtered uric acid back into the systemic circulation. This interaction promotes the retention of uric acid within the renal tubule fluid, initiating a targeted change in the renal handling of this solute.


Modulating Systemic Uric Acid Clearance

This targeted molecular action causes a downstream mechanistic cascade resulting in a substantial and sustained increase in uric acid clearance from the body (uricosuria). The enhanced elimination ultimately adjusts the body's systemic uric acid homeostasis, promoting a reduction of uric acid concentration in the plasma (hypouricemia). This change decreases the saturation point of uric acid in extracellular fluids and tissues, which directly influences the solubility and equilibrium of crystal formation.

Dosage and Administration Information

How to Use Gotur

Gotur (cyclizine) is administered according to specific regimens for both acute and preventive use. The medication is administered via the oral route (using tablets or liquid forms) and the parenteral route (for intravenous and intramuscular injection).


Official Adult Dosing and Frequency

The standard approach defines the maximum quantity and frequency of administration. The usual dose for adults and adolescents 12 years and older is 50 mg per administration. This dose may be repeated up to three times daily, establishing a maximum total daily use of 150 mg.

Dosing for Prevention:

To address motion-related symptoms, the initial oral dose is typically taken one to two hours before departure.


Age-Specific Administration

There are specific guidelines for pediatric use:

  • Children 6 to 12 years: The oral dose is 25 mg, which may be repeated up to three times daily. This is typically achieved by using a scored 50 mg tablet.
  • Children under 6 years: Oral tablets are generally not recommended.
  • Older Adults: The normal adult dosage is considered appropriate.

Administration Conditions

Oral forms of cyclizine may be taken with or without food. When the medication is administered via the intravenous route, it must be given as a slow injection to ensure proper delivery. For administration in clinical settings, the injection solution may require dilution to 5 mg/ml with specific solutions prior to infusion.

Recent Clinical Evidence

Gotur: Recent Clinical Evidence

Overview of Clinical Research

Research explored whether the compound was associated with differences in symptom severity across various study populations. Studies investigated the activity of the compound in laboratory settings. One clinical study examined patient outcomes, including reported measures of life quality, over a 6-month observation period.

Studies also evaluated whether the drug was associated with changes in reported pain and discomfort. Initial research focused on evaluating the drug’s profile in adults aged 18 to 65.


Key Research Findings

Combination Therapy: Research Focus

Studies investigated whether using the drug alongside standard care resulted in different patient outcomes compared to standard care alone. Research focused on potential findings related to combined use and differences in patient-reported outcomes. The findings from this study suggest that the combination approach was explored as an initial treatment option, and further research has explored the long-term outcomes associated with this combined use.

Special Populations and Profile Assessment

Studies evaluated the drug's profile in individuals with mild kidney impairment. Research did not examine the use of the drug in people with severe impairment. Similarly, studies on liver impairment assessed how the drug was managed by individuals classified as having mild or moderate impairment. The drug's use in individuals with severe liver impairment was not the focus of this research.

Dose Optimization

Studies evaluated whether adjusting the dose based on body weight was associated with different outcomes and patient management. This approach to dosing was examined in research regarding patient outcomes and management.

Frequently Asked Questions (FAQ)

Common questions about Gotur (FAQ)

Q: Can Gotur be taken with common over-the-counter pain relievers?

A: Official documentation advises caution when using Gotur with medicines that cause central nervous system (CNS) depression or have anticholinergic activity. Because some pain relievers, cold/flu products, and sleep aids may contain ingredients with these properties, it is necessary to consult with a healthcare provider or pharmacist regarding any over-the-counter medicines, as official information addresses drug class interactions.

Q: Is Gotur safe for people with liver problems?

A: Official information states that use in patients with hepatic disease (liver disease) requires caution and appropriate monitoring. Clinical studies have examined the drug’s profile in individuals with mild or moderate impairment, but not those with severe impairment.

Q: Is Gotur safe for people with kidney problems?

A: Regulatory information indicates that clinical research has evaluated the drug's profile in individuals with mild kidney impairment. No studies focusing on severe kidney impairment have been formally cited in general prescribing information, and use in individuals with underlying kidney conditions is often subject to healthcare professional review.

Q: Why does the official leaflet say I need regular check-ups while taking Gotur?

A: Official documents describe the need for caution and appropriate monitoring in patients with specific pre-existing conditions, such as glaucoma or issues leading to urinary retention, due to the drug's known activity.

Q: Does Gotur interact with common cold or flu medications?

A: Gotur is described as having additive effects with other medications that are CNS depressants or that have anticholinergic action. Since many cold and flu products contain ingredients in these drug classes, official guidance emphasizes the need to consult with a healthcare professional before combining them.

Q: How quickly should I expect to notice Gotur's effects?

A: According to the official product information, the primary antiemetic effect of the medication is typically produced within two hours after administration.

Q: How long does the effect of one dose of Gotur typically last?

A: Official product information states that the therapeutic effect of a single dose generally lasts for about four hours.

Q: Does Gotur have a risk of dependence or addiction?

A: Official labeling highlights that reports of abuse of the active ingredient have been documented, especially when the drug is used outside of recommended guidelines, due to its euphoric or hallucinatory effects. Addiction, dependence, and drug-seeking behavior have been noted in some cases.

Q: Are there generic versions of Gotur available?

A: Gotur is a brand name for the active substance cyclizine. Cyclizine is a well-established compound and is widely available in many countries in multiple generic formulations under various names.

Q: What should I do if I experience a severe, unexpected side effect from Gotur?

A: Official patient information directs users that if a severe or serious adverse reaction is experienced, such as a severe allergic reaction or convulsions, it is necessary to seek emergency medical attention immediately.

Q: Can men and women take Gotur for the same reasons?

A: The general eligibility and contraindication rules for Gotur apply equally to all adults, regardless of gender. The only distinctions noted in official documents relate to the specific, conditional use notes for pregnancy and lactation.

Q: Do any official sources mention long-term safety data for Gotur?

A: Official regulatory documents indicate that continuous long-term use is not generally recommended and is associated with risks noted in the label, including the potential for dependence and in rare instances, nervous system effects known as extrapyramidal motor disturbances.

Q: What time of day is Gotur usually recommended to be taken?

A: The recommended time to take Gotur is dependent on its purpose. For the prevention of motion-related symptoms, official guidance specifies taking the initial dose one to two hours before departure. For other conditions, the specific timing is determined by the prescribing healthcare professional based on symptom onset.

Q: What does the term 'contraindication' mean for Gotur?

A: In regulatory language, a contraindication is a condition or factor that makes taking Gotur inadvisable, as it could potentially cause harm. For example, Gotur is officially contraindicated for use in the presence of acute alcohol intoxication or a condition called porphyria.

Q: Are there any dietary supplements that are known to interfere with Gotur?

A: Official public health guidance recommends that you discuss the use of herbal remedies, vitamins, or general supplements with your healthcare provider or pharmacist, as official information requires that healthcare providers be informed of all concomitant products.

Q: Where can I find the official regulatory documents for Gotur?

A: Official prescribing information is published on government-run drug databases. You can search for the active ingredient, cyclizine, on websites like the FDA DailyMed, the EMA for the Summary of Product Characteristics (SmPC), or your national regulatory authority's website.

Q: Is Gotur used for any conditions other than the main one listed?

A: In addition to its main use for general nausea and vomiting, official indications for use include the treatment of sickness caused by motion sickness, narcotic analgesics, post-operative vomiting, and vomiting associated with certain types of radiotherapy.

Q: Is Gotur processed by the liver or the kidneys?

A: Official product information states that the active ingredient is metabolized in the body to its derivative, norcyclizine. The elimination half-life—the time required for half the drug to be cleared—is described as approximately 13 to 20 hours.

Q: How is Gotur typically stopped or discontinued?

A: If Gotur has been taken regularly for a long period of time, official guidance indicates that discontinuation should be gradual. The specific cessation process is determined by the prescribing healthcare professional.

Q: What if Gotur doesn't seem to be working for me after the expected time?

A: Official public guidance recommends that if your condition worsens or your symptoms persist after the expected onset time, you should contact your healthcare provider for further advice.

Q: Is Gotur a relatively new medicine or has it been used for a long time?

A: The active ingredient in Gotur, cyclizine, has been in use for a long time within the medical community. It was first approved by some regulatory bodies for medical use as far back as the early 1980s.

How should Gotur be stored and disposed of?

How to Store and Dispose of Gotur (Cyclizine)

Gotur must be stored according to official regulatory requirements to ensure stability. Both the tablets and injection should be stored at Controlled Room Temperature, which is between 20 C and 25 C. The tablets require protection from moisture, and both forms must be stored away from excessive heat. The injectable solution must also be protected from light and must not be frozen.

All forms of this medicine must be kept out of the sight and reach of children.

Disposal Requirements

Unused or expired Gotur must not be disposed of in household waste or flushed down the toilet. Regulators specify that medicine should be returned to a pharmacist or a local collection program for proper handling as pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gotur found in:

A-Z Index: